Q1 FY27 results: Revenue up 13%, PAT falls 22% on margin pressure
ACI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.8 pts less than Nifty Microcap 250 and 6.1 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q1 FY27 standalone revenue rose 13% YoY to Rs 31,593 lakhs, but PAT fell 22% to Rs 4,053 lakhs as other expenses and finance costs compressed EBITDA margins from 33% to 25%. Consolidated PAT dropped 24% to Rs 3,035 lakhs. Company invested Rs 17,000 lakhs into subsidiary Acume Chemicals. Step-down subsidiary Sicsem signed a fiscal support pact with India Semiconductor Mission for up to 75% capital support. Auditors gave an unmodified review.
Topline growth is positive, but sharp PAT decline and margin compression may pressure the stock. Subsidiary investments and semiconductor foray offer future optionality.